Skip to content
Teethgrinder – Lifestyle
Author:
Tessera Therapeutics
Tessera Therapeutics to Present New Preclinical Data Supporting its In Vivo Sickle Cell Disease Program and In Vivo CAR-T Applications at the 68th American Society of Hematology Annual Meeting
November 4, 2026
Tessera Therapeutics Appoints Joseph Romanelli as President and Chief Executive Officer
July 23, 2026
Tessera Therapeutics Showcases New Preclinical Data Advancing In Vivo Program in Sickle Cell Disease and CAR-T Applications at the American Society of Gene and Cell Therapy 29th Annual Meeting
May 14, 2026